Nikolay Kislov

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

Miguel Martín, Elgene Lim, Mariana Chávez‐MacGregor et al. · Journal of Clinical Oncology · 2024 · 63 citations · Full text

Medicine, Oncology, Pharmacology +17

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial

Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama et al. · The Lancet · 2025 · 47 citations · Full text

Medicine, Oncology, Urology +13

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

David R. Spigel, Afshin Dowlati, Yuanbin Chen et al. · Journal of Clinical Oncology · 2024 · 35 citations · Full text

Medicine, Oncology, Pharmacology +15

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

Mehmet Asım Bilen, Brian I. Rini, Martin H. Voss et al. · Clinical Cancer Research · 2021 · 34 citations · Full text

Medicine, Oncology, Pharmacology +9